We've collected the top tweets from Tuesday, June 9! Show us your work station, tell us about your favorite session or quote from #BIODigital
"We need to get serious about diversity in our industry because we need to represent the people we are trying to serve and we aren't even close. " - @melindarichter@JNJInnovation@JLABS@WomenInBio#BioDigital with @FishburnSimone of @BioCentury
— Chelsea Hewitt (@chelsbells4) June 9, 2020
The #biopharma industry has "stepped to the plate" on #COVID19, says @NIH Dr. Anthony Fauci #BIODigital#DrFaucipic.twitter.com/X88t2616ax
— I Am Biotech (@IAmBiotech) June 9, 2020
To @DrMichelleBIO, Fauci shares, “If you’re a scientist, or in a position of leadership in science—you have to stick to the science. You can’t compromise that. That’s your job. Science in the interest of public health.” #BIODigitalpic.twitter.com/QgxLcnkUTk
— Johnson & Johnson Innovation (@JNJInnovation) June 9, 2020
#BIODigital is a fan of Dr. Anthony Fauci! Like what you heard during today's session? To show your love of Fauci everyday, visit our online store 💙https://t.co/MLCNWu8zZEpic.twitter.com/Ro0253tS8h
— BIO Convention (@BIOConvention) June 9, 2020
Across the board, developing a COVID-19 vaccine is a #TeamEffort. #JNJ’s Paul Stoffels@theNAMedicine & former #FDA's Peggy Hamburg@Novavax's Greg Glenn@US_FDA's Peter Marks@Sanofi's Gary Nabel
— Johnson & Johnson Innovation (@JNJInnovation) June 9, 2020
#NothingStopsInnovation#BIODigitalpic.twitter.com/0eClNQwVtF
Thank you again to Dr. Fauci for joining us for #BIODigital@nytimes: The nation’s leading infectious disease expert tells biotech executives that Covid-19 has inflicted global damage, exposing worrisome racial disparities.https://t.co/MU1kemW1kj
— Dr. Michelle McMurry-Heath (@DrMichelleBIO) June 9, 2020
Dr. Anthony Fauci says coronavirus turned 'out to be my worst nightmare' and it 'isn't over' https://t.co/vHfytMC2MH
— CNBC (@CNBC) June 9, 2020
News from #BIODigital: "Price Limits Will Scare Off Covid Vaccine Makers, Fauci Warns"
— BIO Convention (@BIOConvention) June 9, 2020
via @BLawhttps://t.co/v1I0NyMqOp
#News from @BIOConvention: We have been evaluating our medicines currently in development for treatment of secondary complications of COVID-19 and started a phase II clinical trial of a monoclonal antibody in May.
— GSK US (@GSKUS) June 9, 2020
Outgoing BIO President & CEO @JimGreenwood shares what's at stake right now for the #biotech industry and what the future might hold. #BIODigitalpic.twitter.com/RUxNJmT4tv
— BIO Convention (@BIOConvention) June 9, 2020